Tonix Pharmaceuticals shares are trading higher by 22.5% during Monday's session. The company announced that the FDA will not ...

Shares of Tonix Pharmaceuticals are pulling back 12.7% during Thursday's session. The stock is pulling back following a regulatory update on its experimental fibromyalgia treatment, TNX-102 SL.

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has surged by 10.44%, which has investors questioning if this is right ...

Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) plummeted 19% lower on Wednesday noon after the company reported ...

as evidenced by the stock's significant rise in the trading session. If TNX-102 SL receives approval, it could mark a major milestone for Tonix Pharmaceuticals and offer a new treatment option for ...

Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) plunged ~21% in the morning hours on Wednesday after the biotech fell short of Street forecasts with its Q4 2024 revenue ahead of a potential FDA nod ...

The FDA previously granted Fast Track designation to TNX-102 SL for the management of fibromyalgia in 2024, a designation intended to expedite FDA review of important new drugs to treat serious ...

A copy of the Company’s poster will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be ...

FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.

Investors have responded positively to the news, as evidenced by the stock’s significant rise in the trading session. If TNX-102 SL receives approval, it could mark a major milestone for Tonix ...